- Covalent Occlusion of the RORγt Ligand Binding Pocket Allows Unambiguous Targeting of an Allosteric Site
-
The nuclear receptor RORγt is a key positive regulator in the differentiation and proliferation of T helper 17 (Th17) cells and the production of proinflammatory cytokines like IL-17a. Dysregulation of this pathway can result in the development of various
- Meijer, Femke A.,Van Den Oetelaar, Maxime C. M.,Doveston, Richard G.,Sampers, Ella N. R.,Brunsveld, Luc
-
supporting information
p. 631 - 639
(2021/04/07)
-
- Structure-activity relationships for lipoprotein lipase agonists that lower plasma triglycerides in vivo
-
The risk of cardiovascular events increases in individuals with elevated plasma triglyceride (TG) levels, therefore advocating the need for efficient TG-lowering drugs. In the blood circulation, TG levels are regulated by lipoprotein lipase (LPL), an unstable enzyme that is only active as a non-covalently associated homodimer. We recently reported on a N-phenylphthalimide derivative (1) that stabilizes LPL in vitro, and moderately lowers triglycerides in vivo (Biochem. Biophys. Res. Commun. 2014, 450, 1063). Herein, we establish structure-activity relationships of 51 N-phenylphthalimide analogs of the screening hit 1. In vitro evaluation highlighted that modifications on the phthalimide moiety were not tolerated and that lipophilic substituents on the central phenyl ring were functionally essential. The substitution pattern on the central phenyl ring also proved important to stabilize LPL. However, in vitro testing demonstrated rapid degradation of the phthalimide fragment in plasma which was addressed by replacing the phthalimide scaffold with other heterocyclic fragments. The in vitro potency was retained or improved and substance 80 proved stable in plasma and efficiently lowered plasma TGs in vivo.
- Caraballo, Rémi,Larsson, Mikael,Nilsson, Stefan K.,Ericsson, Madelene,Qian, Weixing,Tran, Nam Phuong Nguyen,Kindahl, Tomas,Svensson, Richard,Saar, Valeria,Artursson, Per,Olivecrona, Gunilla,Enquist, Per-Anders,Elofsson, Mikael
-
p. 191 - 209
(2015/09/15)
-
- NEW PLASMA LIPID LOWERING AGENTS
-
The present invention relates to new plasma lipid lowering compounds and pharmacological compositions,and their use in the prophylaxis, prevention and treatment of hyperlipidemia, including hypertriglyceridemia, hyperlipoproteinemia, and hypercholesterolemia, as well as hyperlipidemia-related diseases.
- -
-
Page/Page column 21; 22
(2015/12/24)
-
- Discovery of halo-nitrobenzamides with potential application against human African trypanosomiasis
-
A series of halo-nitrobenzamide were synthesized and evaluated for their ability to block proliferation of Trypanosoma brucei brucei. A number of these compounds had significant activity against the parasite, particularly 2-chloro-N-(4-chlorophenyl)-5-nitrobenzamide 17 which exhibited low micromolar inhibitory potency against T. brucei and selectivity towards both malaria and mammalian cells.
- Hwang, Jong Yeon,Smithson, David,Connelly, Michele,Maier, Julie,Zhu, Fangyi,Guy, Kiplin R.
-
supporting information; experimental part
p. 149 - 152
(2010/04/29)
-
- PPAR-gamma modulator
-
A compound of the following formula or a pharmacologically acceptable salt thereof: 1 wherein A represents a phenyl group or the like, B represents an aryl group or the like, X represents an oxygen atom or the like, and n represents 0 or 1. The compound is a PPAR γ modulator which is a therapeutic agent for retrograde osteoporosis in which excessive differentiation of adipocytes is inhibited and formation and differentiation of osteoblasts from stem cells is facilitated, and for diabetes mellitus without characteristics such as excessive adipogenesis, liver dysfunction, vascular disorders, heart diseases and the like.
- -
-
-